The three companies have jointly conducted clinical trials of antibody-coupled drugs to treat urethra skin cancer
-
Last Update: 2021-02-22
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Seattle Genetics and Astellas announced a partnership agreement with Mercedon to jointly conduct clinical trials of the antibody conceding drug (ADC) Enfortumab Vedotin and Keytruda for the first-line treatment of locally advanced or metastatic urethra cancer.The three companies will fund the launch of a Global Registration Phase III study, led by Seattle Genetics, which is currently in communication with regulators about the design of the trial, which is expected to start in the first half of 2020.Enfortumab Vedotin has filed a listing application with the FDA for locally advanced or metastatic urethroid skin cancer with PD-1/L1 inhibitors and platinum-containing new assisted chemotherapy/assisted chemotherapy, and is currently undergoing FDA review with the PDUFA date of March 15 next year.Enfortumab vedotin uses Seattle Genetics' proprietary connectivity technology to connect the micro-tube destroyer MMAE to the anti-Netin-4 monoclonal antibody.Enfortumab vedotin targets the cell adhesion molecule Nectin-4, expressed on a variety of solid tumors. (Drug Information Network)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
